Bridging paradigms and shaping the future of resectable gastric cancer: a narrative review of the post-MATTERHORN era - PubMed
a day ago
- #immunotherapy
- #perioperative chemotherapy
- #gastric cancer
- Gastric or gastroesophageal junction cancer (GC/GEJC) is the fifth leading cause of cancer-related mortality worldwide.
- Curative-intent surgery is the cornerstone of treatment for locally advanced GC/GEJC, but recurrence remains a significant issue.
- Perioperative FLOT chemotherapy is the standard of care in Western countries, while surgery followed by adjuvant chemotherapy is standard in Asia.
- The PRODIGY and RESOLVE trials support neoadjuvant and perioperative strategies in Asia, promoting global harmonization.
- The MATTERHORN trial demonstrated significant improvements in event-free and overall survival with durvalumab added to perioperative FLOT.
- This trial provides the first global phase III evidence for integrating immune checkpoint inhibitors with perioperative chemotherapy in GC/GEJC.
- The review highlights the paradigm shift in perioperative treatment and challenges in implementing FLOT plus durvalumab in practice.
- Future directions include molecularly targeted therapies and novel multimodal approaches.
- The MATTERHORN trial marks a new era in the management of resectable GC/GEJC.